Helixmith Obtains Certification for Advanced Technology and Product Verification from Ministry of Trade, Industry and Energy

[Asia Economy Reporter Jang Hyowon] Helixmith announced on the 14th that it has obtained the ‘Advanced Technology and Product Confirmation Certificate’ from the Ministry of Trade, Industry and Energy (hereinafter referred to as the Ministry) for its gene therapy ‘Engensis (VM202)’.

The Ministry’s Advanced Technology and Product Confirmation Certificate is awarded to companies with outstanding technology, considering technology intensity, speed of innovation, and the technical and economic ripple effects of the technology, aiming to promote the advancement of industrial structure.

Helixmith’s Engensis was recognized as corresponding to the ‘Therapeutic Gene Discovery and Optimization Technology’ in the bio sector according to Article 5 of the Ministry’s Industrial Development Act and Article 5 of the Notification on the Scope of Advanced Technologies and Products.

Engensis is a drug composed of plasmid DNA expressing hepatocyte growth factor (HGF) protein. Through 15 years of research and clinical trials, it can produce HGF protein in vivo with a simple intramuscular injection, demonstrating effects such as nerve regeneration, angiogenesis, and prevention of muscle atrophy.

Yoo Seungshin, CEO of Helixmith, said, “We will continue to invest in and strive for technological capabilities to leap forward as a global gene therapy company representing the Republic of Korea in the world market.”

This content was produced with the assistance of AI translation services.